1 EVERTRUST PLAZA, JERSEY CITY, NJ
SCYNEXIS Increases Authorized Shares to 65 Million; Stockholder Approval Rece...
SCYNEXIS, Inc. Implements 1-for-8 Reverse Stock Split and Share Reduction
Material disclosure
Director Retirement - Steven C. Gilman Steps Down from SCYNEXIS Board
Announces $40.0 Million Private Placement
Investor Presentation
Ex-99.1
Binding MOU for Amendment to Exclusive License Agreement with GSK
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Submission Upload
Correspondence
Free Writing Prospectus